Monica Gandhi, MD, MPH

Headshot of Monica Gandhi
User Profile Photo

Monica Gandhi, MD, MPH

User Profile Name
Director, UCSF-Bay Area CFAR
Professor, School of Medicine
User Profile Title
User Profile Email

Biography

Dr. Gandhi has been at UCSF since 1996 when she came here for her medical residency after attending Harvard Medical School. She completed an ID fellowship at UCSF from 1999-2003 and a Masters’ in Public Health in Epidemiology/Biostatistics from the University of California, Berkeley in 2001, as well as a Traineeship in AIDS Prevention Studies (TAPS) post-doctoral fellowship. She has been an NIH funded researcher since 2003, first with a K23 award and now with multiple R01 and R21 grants to help run the UCSF Hair Analytical Laboratory (HAL), a laboratory that focuses on objective adherence metrics to HIV treatment and prevention for multiple UCSF-based and global investigators in hair and urine. She served on the Office of AIDS Research Advisory Committee (OARAC) from 2014-2017 and Chair from 2017-2018. She also serves on the ACTG Executive Committee. She has served as the co-director of the CFAR Mentoring Program for the past five years and has a dedicated interest in HIV mentorship and education.

Dr. Gandhi serves as the Medical Director of the Ward 86 HIV Clinic (since January 2014) and won the HIV Medical Association (HIVMA) Clinical Educator Award in 2017 and was awarded the Master Clinician award in the Department of Medicine in 2019. Beyond an interest in adherence metrics and PrEP, Dr. Gandhi has a special interest in HIV and women and sex differences in HIV medicine. She is thrilled to serve in this role to support the HIV/AIDS researcher community across UCSF and our many affiliates. She is especially interested in mentoring early stage investigators, especially those from underrepresented racial/ethnic minorities, from disadvantaged backgrounds, and with disabilities. Monica plans an open door policy with the CFAR community here at UCSF and is excited to serve with you all in continuing to make UCSF an innovative and exciting place to conduct HIV research.

User Profile Bio

Displaying 51 - 75 of 291

  1. Starks TJ, Adebayo T, Kyre KD, Millar BM, Stratton MJ, Gandhi M, Ingersoll KS. Pilot Randomized Controlled Trial of Motivational Interviewing with Sexual Minority Male Couples to Reduce Drug Use and Sexual Risk: The Couples Health Project. AIDS Behav. 2022 Feb; 26(2):310-327.
  2. Apornpong T, Grinsztejn B, Hughes M, Ritz J, Kerr SJ, Fletcher CV, Ruxrungtham K, Godfrey C, Gross R, Hogg E, Wallis CL, Badal-Faesen S, Hosseinipour MC, Mngqbisa R, Santos BR, Shah S, Hovind LJ, Mawlana S, Van Schalkwyk M, Chotirosniramit N, Kanyama C, Kumarasamy N, Salata R, Collier AC, Gandhi M, for A5288 study team. Antiretroviral hair levels, self-reported adherence, and virologic failure in second-line regimen patients in resource-limited settings. AIDS. 2021 07 15; 35(9):1439-1449.
  3. DeJong C, Spinelli MA, Okochi H, Gandhi M. Tenofovir-based PrEP for COVID-19: an untapped opportunity? AIDS. 2021 07 15; 35(9):1509-1511.
  4. Imbert E, Hickey MD, Clemenzi-Allen A, Lynch E, Friend J, Kelley J, Conte M, Das D, Rosario JBD, Collins E, Oskarsson J, Hicks ML, Riley ED, Havlir DV, Gandhi M. Evaluation of the POP-UP programme: a multicomponent model of care for people living with HIV with homelessness or unstable housing. AIDS. 2021 07 01; 35(8):1241-1246.
  5. Reckers A, Wu AHB, Ong CM, Gandhi M, Metcalfe J, Gerona R. A combined assay for quantifying remdesivir and its metabolite, along with dexamethasone, in serum. J Antimicrob Chemother. 2021 06 18; 76(7):1865-1873.
  6. Riley ED, Hickey MD, Imbert E, Clemenzi-Allen AA, Gandhi M. Coronavirus Disease 2019 (COVID-19) and HIV Spotlight the United States Imperative for Permanent Affordable Housing. Clin Infect Dis. 2021 06 01; 72(11):2042-2043.
  7. Spinelli MA, Lowery B, Shuford JA, Spindler J, Kearney MF, McFarlane JR, McDonald C, Okochi H, Phung N, Kuncze K, Jee K, Johannessen D, Anderson PL, Smith DK, Defechereux P, Grant RM, Gandhi M. Use of Drug-level Testing and Single-genome Sequencing to Unravel a Case of Human Immunodeficiency Virus Seroconversion on Pre-exposure Prophylaxis. Clin Infect Dis. 2021 06 01; 72(11):2025-2028.
  8. Lodi S, Emenyonu NI, Marson K, Kwarisiima D, Fatch R, McDonell MG, Cheng DM, Thirumurthy H, Gandhi M, Camlin CS, Muyindike WR, Hahn JA, Chamie G. The Drinkers' Intervention to Prevent Tuberculosis (DIPT) trial among heavy drinkers living with HIV in Uganda: study protocol of a 2×2 factorial trial. Trials. 2021 May 20; 22(1):355.
  9. Beck A, Gandhi M. Adjudicating Reasons for Hospitalization Reveals That Severe Illness From COVID-19 in Children Is Rare. Hosp Pediatr. 2021 08; 11(8):e159-e160.
  10. Peluso MJ, Dee L, Shao S, Taylor J, Campbell D, Collins S, Gandhi M, Johnston R, Deeks SG, Sauceda JA, Dubé K. Operationalizing Human Immunodeficiency Virus Cure-related Trials with Analytic Treatment Interruptions During the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Pandemic: A Collaborative Approach. Clin Infect Dis. 2021 05 18; 72(10):1843-1849.
  11. Appa A, Rodda LN, Cawley C, Zevin B, Coffin PO, Gandhi M, Imbert E. Drug Overdose Deaths Before and After Shelter-in-Place Orders During the COVID-19 Pandemic in San Francisco. JAMA Netw Open. 2021 05 03; 4(5):e2110452.
  12. Gandhi M, Bacon O, and AB Caughey. . Blueprints Clinical Cases in Medicine. 2021.
  13. Spinelli MA, Lynch KL, Yun C, Glidden DV, Peluso MJ, Henrich TJ, Gandhi M, Brown LB. SARS-CoV-2 seroprevalence, and IgG concentration and pseudovirus neutralising antibody titres after infection, compared by HIV status: a matched case-control observational study. Lancet HIV. 2021 06; 8(6):e334-e341.
  14. Thuo N, Polay M, Leddy AM, Ngure K, Chatterhee P, Gandhi M, Amico KR. Point-of-Care Test for Assessing Tenofovir Adherence: Feasibility and Recommendations from Women in an Oral PrEP Program in Kenya and Their Healthcare Providers. AIDS Behav. 2021 Nov; 25(11):3617-3629.
  15. Johnson KA, Niu X, Glidden DV, Castillo-Mancilla JR, Yager J, MaWhinney S, Morrow M, Okochi H, Cressey TR, Drain PK, Gandhi M, Anderson PL, Spinelli MA. Lower Urine Tenofovir Concentrations Among Individuals Taking Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate: Implications for Point-of-Care Testing. Open Forum Infect Dis. 2021 Jul; 8(7):ofab200.
  16. Herbertson EC, Lahiri CD, Nwogu JN, Soremekun RO, Olugbake OA, Ezechi OC, Akanmu AS, Gandhi M. High Acceptability of Donating Hair and Other Biological Samples for Research Among People Living with HIV in an Outpatient Clinic in Lagos, Nigeria. AIDS Res Hum Retroviruses. 2021 09; 37(9):676-682.
  17. Spinelli MA, Rutherford G, Gandhi M. Lowering SARS-CoV-2 viral load might affect transmission but not disease severity in secondary cases - Authors' reply. Lancet Infect Dis. 2021 07; 21(7):915-916.
  18. Okochi H, Louie A, Phung N, Zhang K, Tallerico RM, Kuncze K, Spinelli MA, Koss CA, Benet LZ, Gandhi M. Tenofovir and emtricitabine concentrations in hair are comparable between individuals on tenofovir disoproxil fumarate versus tenofovir alafenamide-based ART. Drug Test Anal. 2021 Jul; 13(7):1354-1370.
  19. Gandhi M, Beyrer C, Goosby E. Masks Reduce Viral Inoculum of SARS-CoV2. J Gen Intern Med. 2021 04; 36(4):1124-1125.
  20. Santiago-Rodriguez EI, Maiorana A, Peluso MJ, Hoh R, Tai V, Fehrman EA, Hernandez Y, Torres L, Spinelli MA, Gandhi M, Kelly JD, Martin JN, Henrich TJ, Deeks SG, Sauceda JA. Characterizing the COVID-19 illness experience to inform the study of post-acute sequelae and recovery: a qualitative study. medRxiv. 2021 Mar 24.
  21. Spinelli MA, Hessol NA, Schwarcz SK, Scheer S, Gandhi M, Chin Hsu L. Disparities in Integrase Inhibitor Usage in the Modern HIV Treatment Era: A Population-Based Study in a US City. Open Forum Infect Dis. 2021 Jul; 8(7):ofab139.
  22. Tabrisky AP, Coffin LS, Olem DP, Neilands TB, Johnson MO. Couples-focused intervention to improve engagement in HIV care: protocol for a randomised controlled trial. BMJ Open. 2021 03 22; 11(3):e037468.
  23. Kiang MV, Chin ET, Huynh BQ, Chapman LAC, Rodríguez-Barraquer I, Greenhouse B, Rutherford GW, Bibbins-Domingo K, Havlir D, Basu S, Lo NC. Routine asymptomatic testing strategies for airline travel during the COVID-19 pandemic: a simulation study. Lancet Infect Dis. 2021 07; 21(7):929-938.
  24. Peluso MJ, Takahashi S, Hakim J, Kelly JD, Torres L, Iyer NS, Turcios K, Janson O, Munter SE, Thanh C, Nixon CC, Hoh R, Tai V, Fehrman EA, Hernandez Y, Spinelli MA, Gandhi M, Palafox MA, Vallari A, Rodgers MA, Prostko J, Hackett J, Trinh L, Wrin T, Petroplolous CJ, Chiu CY, Norris PJ, DiGermanio C, Stone M, Busch MP, Elledge SK, Zhou XX, Wells JA, Shu A, Kurtz TW, Pak JE, Wu W, Burbelo PD, Cohen JI, Rutishauser RL, Martin JN, Deeks SG, Henrich TJ, Rodriguez-Barraquer I, Greenhouse B. SARS-CoV-2 antibody magnitude and detectability are driven by disease severity, timing, and assay. medRxiv. 2021 Mar 05.
  25. Peluso MJ, Takahashi S, Hakim J, Kelly JD, Torres L, Iyer NS, Turcios K, Janson O, Munter SE, Thanh C, Nixon CC, Hoh R, Tai V, Fehrman EA, Hernandez Y, Spinelli MA, Gandhi M, Palafox MA, Vallari A, Rodgers MA, Prostko J, Hackett J, Trinh L, Wrin T, Petroplolous CJ, Chiu CY, Norris PJ, DiGermanio C, Stone M, Busch MP, Elledge SK, Zhou XX, Wells JA, Shu A, Kurtz TW, Pak JE, Wu W, Burbelo PD, Cohen JI, Rutishauser RL, Martin JN, Deeks SG, Henrich TJ, Rodriguez-Barraquer I, Greenhouse B. SARS-CoV-2 antibody magnitude and detectability are driven by disease severity, timing, and assay. medRxiv. 2021 Mar 05.